# Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

> **NCT04510818** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Head and Neck Cancer
- Esophageal Squamous Cancer

## Interventions

- **DRUG:** Capecitabine, Camrelizumab

## Key facts

- **NCT ID:** NCT04510818
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510818, "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04510818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*